Cancer Vaccine Institute News

The US National Cancer Institute (NCI) and the Foundation for the National Institutes of Health have partnered to raise nearly $200 million to fund cancer vaccine clinical trials, including mRNA-based approaches for patients at high risk for tumor recurrence. Dr. Nora Disis In a recent article from Lancet Oncology,  Dr. Nora Disis, Director of the Cancer Vaccine Institute (CVI), called the initiative a promising start, but commented that the scale of the investment remains sm

Dr. Denise Cecil, CVI Principal Scientist. PC: AP Photos Colon cancer is the second leading cause of cancer death in the United States, with diagnoses rising among adults under 55. In response, the Cancer Vaccine Institute (CVI) at UW Medicine is developing COLOVAC, a first-in-class vaccine designed to intercept colon cancer at its earliest stages, offering hope to those at the highest risk. Rising Colon Cancer Risk Colon cancer remains one of the most consequential cancers o

The Cancer Vaccine Institute (CVI) is proud to highlight a recent JAMA Oncology  Viewpoint co‑authored by our Executive Director, Dr. Kiran Dhillon, and Dr. Lennard Lee of the University of Oxford, outlining why the time for cancer vaccines is now. For decades, the U.S. has invested in the science, infrastructure, and talent needed to make cancer vaccines possible. Early clinical data now show that these vaccines are safe, effective, and already providing meaningful benefits

The Cancer Vaccine Institute (CVI) took park in the 2025 San Antonio Breast Cancer Symposium from December 9-12, 2025, bringing our latest research to one of the world's leading forums for breast cancer science. Faculty members from the CVI presented four scientific posters with fellow collaborators, researchers, and scientists. Through these presentations, the CVI team highlighted recent discoveries in HER2-targeted vaccines, neoadjuvant immunotherapy, and findings from our

Every year, In Concert for Cancer brings people together through music, hope, and a shared commitment to ending cancer. At the Cancer Vaccine Institute (CVI), that commitment translates directly into momentum by fueling discoveries and supporting the people who will carry this mission forward. This year, their partnership is helping accelerate one of the most ambitious goals in cancer research: preventing ovarian cancer before it starts. And at the heart of that effort is a